Establishing a New Ultrasound Technique to Improve Assessment of Chronic Kidney Disease.
Validation of Contrast Enhanced Ultrasound (CEUS) for the Assessment of Renal Perfusion Using Renal Magnetic Resonance Imaging (MRI) in Chronic Kidney Disease (CKD
Blood flow to the kidneys is important in the development of kidney diseases. Currently we do not have ways of measuring and monitoring kidney blood flow for patients in real-time. This is a major barrier to investigation and management of acute kidney injury (AKI) and chronic kidney disease (CKD).
Kidney blood flow can be reliably measured using a specialised type of MRI scan, but this is expensive and difficult to do in people who are unwell. Contrast-enhanced ultrasound (CEUS) is a new technique, which uses a contrast containing microbubbles to measure blood flow. The benefits of this method are that it is relatively inexpensive, the contrast agents are not kidney-damaging and it can be done at the bedside.
We want to compare contrast enhanced ultrasound against the current best-measure of kidney blood flow, to see if it is giving accurate information about kidney blood flow. We will do this by doing both MRI and contrast enhanced ultrasound scans in people with chronic kidney disease and comparing the results.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Renal perfusion, the delivery of oxygenated blood to kidney tissues, is relevant to a number of acute and chronic kidney diseases. Despite this, we do not have methods in current clinical practice to measure renal perfusion and monitor the response to supportive treatments in real time. This is a major barrier to investigation and management of acute kidney injury (AKI) and chronic kidney disease (CKD).
The current non-invasive gold standard technique for renal perfusion measurement is arterial-spin labelling magnetic resonance imaging (ASL-MRI), which has been validated against other measures of perfusion, including contrast agent-based methods. However, MRI has limitations including high cost, and logistical barriers. Therefore, validation of a bed-side measurement tool for renal perfusion would be of significant clinical importance.
This proposal aims to validate CEUS renal cortical perfusion measurement by comparison with quantifiable ASL-MRI parameters of renal microvascular perfusion in individuals with CKD.
TRIAL REGIMEN
All interventions outlined below are for the purposes of research, not usual care.
Study day:
All participants will attend fasted for preceding 2 hours. Demographic details and medical history will be recorded. The patient's concomitant medications which form part of their usual care will be recorded. These will not be adjusted.
Results of blood and urine tests that are collected as part of clinical care will be recorded.
Participants will undergo two scanning sessions, the first using renal MRI at the Sir Peter Mansfield Imaging Centre (SPMIC) to provide a quantitative measure of renal perfusion, and the second to provide the comparator measure of renal perfusion using CEUS performed at Royal Derby Hospital.
Outcomes:
MRI derived perfusion variables: peak time, and peak signal intensity (SI) will be obtained from time intensity curves.
Mean flow velocity (cm/s), cross-sectional area of the lumen (mm2), and hence bulk renal blood flow (ml/s)
CEUS derived perfusion parameters: acoustic index (AU); mean transit time (seconds); perfusion index, which is the ratio of AI to mTT; and wash-in rate (seconds)
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kerry Horne, BMBCh
- Phone Number: 07469037422
- Email: kerry.horne@nottingham.ac.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- CKD 3b or CKD4
- Ability to give informed consent
Exclusion Criteria:
- Autosomal dominant polycystic kidney disease
- Solid organ transplant
- Pregnant women
- Known allergy to Sonovue
- Contraindications to MRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Participants with CKD having MRI and CEUS
10 participants with CKD will have an MRI scan and a contrast enhanced ultrasound scan.
The two scans will be done within 7 days of each other.
|
Contrast enhanced ultrasound using Sonovue microbubble contrast
Arterial-spin labelling magnetic resonance imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between ASL-MRI measures of cortical perfusion (ml/ 100g/min) and CEUS measures of renal microvascular blood flow.
Time Frame: MRI scan and contrast enhanced ultrasound scan to be performed within 7 days of each other.
|
The primary outcome will be the correlation between ASL-MRI measures of cortical perfusion (ml/ 100g/min) and CEUS measures of renal microvascular blood flow.
As CEUS and ASL-MRI generate different units of measurement, correlations (rather than Bland-Altman analyses) will be used.
We will define an ideal result as correlation coefficient r≥0.65, and adequate correlation coefficient r≥0.4.
|
MRI scan and contrast enhanced ultrasound scan to be performed within 7 days of each other.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Repeatability of the CEUS measurements
Time Frame: 1 scan
|
Repeatability of markers of perfusion between 5 flash-reperfusion sequences taken during 1 scan session
|
1 scan
|
|
Correlation between global perfusion from PC-MRI corrected flow measures and CEUS
Time Frame: MRI scan and CEUS done within 7 days of each other
|
As CEUS and ASL-MRI generate different units of measurement, correlations (rather than Bland-Altman analyses) will be used.
We will define an ideal result as correlation coefficient r≥0.65, and adequate correlation coefficient r≥0.4.
|
MRI scan and CEUS done within 7 days of each other
|
|
Correlation between kinetic time-intensity parameters of CEUS and time-resolved MRA
Time Frame: MRI scan and CEUS done within 7 days of each other
|
As CEUS and ASL-MRI generate different units of measurement, correlations (rather than Bland-Altman analyses) will be used.
We will define an ideal result as correlation coefficient r≥0.65, and adequate correlation coefficient r≥0.4.
|
MRI scan and CEUS done within 7 days of each other
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nick Selby, University of Nottingham
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.